A carregar...
Phase I Safety, Pharmacokinetics, and Pharmacogenetics Study of the Antituberculosis Drug PA-824 with Concomitant Lopinavir-Ritonavir, Efavirenz, or Rifampin
There is an urgent need for new antituberculosis (anti-TB) drugs, including agents that are safe and effective with concomitant antiretrovirals (ARV) and first-line TB drugs. PA-824 is a novel antituberculosis nitroimidazole in late-phase clinical development. Cytochrome P450 (CYP) 3A, which can be...
Na minha lista:
| Formato: | Artigo |
|---|---|
| Idioma: | en |
| Publicado em: |
American Society for Microbiology
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4135849/ https://ncbi.nlm.nih.gov/pubmed/24957823 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.03332-14 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|